GlassScriptPhysician profile
Lawrence S Beck
NPI 1992731889
$12,722.71
in general payments reported to CMS, 2019-2025
45 companies · $1,888 in 2025
The $1,888 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,738 · 2020: $1,287 · 2021: $2,699 · 2022: $1,636 · 2023: $1,780 · 2024: $1,694 · 2025: $1,888.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,361.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,997.49 | 2021-2025 | Qulipta, Botox, Ubrelvy |
| Novartis Pharmaceuticals Corporation | $1,590.39 | 2019-2025 | |
| Genentech USA, INC. | $1,043.17 | 2019-2025 | Ocrevus Zunovo, Ocrevus |
| Ucb, INC. | $875.36 | 2019-2025 | Briviact, Rystiggo, Nayzilam |
| Biogen, INC. | $795.65 | 2019-2023 | Vumerity, Tysabri |
| Sk Life Science, INC. | $681.54 | 2020-2025 | |
| Pfizer INC. | $585.97 | 2023-2025 | |
| Teva Pharmaceuticals USA, INC. | $542.33 | 2019-2025 | Ajovy, Austedo Xr |
| Argenx US, INC. | $410.11 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Acadia Pharmaceuticals INC | $330.64 | 2019-2025 | Nuplazid |
| Amneal Pharmaceuticals LLC | $317.99 | 2019-2025 | Rytary, Lyvispah, Crexont |
| Lilly USA, LLC | $255.83 | 2019-2025 | Kisunla, Amyvid |
| Alexion Pharmaceuticals, INC. | $240.04 | 2019-2025 | Ultomiris |
| Eisai INC. | $236.00 | 2019-2025 | |
| Emd Serono, INC. | $234.01 | 2019-2025 | Mavenclad |
Show all 45 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lawrence Beck listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.